post-trial access

Patients

Companies have a practical and ethical responsibility to continue treating patients when clinical trial data collection ends mid-trial.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.